Histologische und molekulare Diagnostik als Grundlage für typadaptierte Behandlung und Management kutaner Lymphome[1]

Zusammenfassung

Kutane T-Zell-Lymphome stellen extranodale Non-Hodgkin-Lymphome reifer T-Lymphozyten dar, die die Haut als Zielorgan haben, dort zu Beginn verbleiben und proliferieren. Sie zeigen eine große Bandbreite klinischer und histologischer Erscheinungsformen und Merkmale. Im Gegensatz zu den nodalen Lymphomen sind ca. 80 % der kutanen Lymphome T-Zell-Lymphome (CTCL, engl. cutaneous T cell lymphoma) und ca. 10 – 20 % B-Zell-Lymphome (CBCL, engl. cutaneous B cell lymphoma). Der Rest entspricht seltenen Entitäten wie die CD4+/CD56+-hämatodermischen Lymphome, deren Ursprungszelle Typ 2 dendritischen Zellen entsprechen. Aufgrund der Heterogenität der kutanen Lymphome und ihrer unterschiedlichen biologischen Potenz, die von einem benigne-indolenten bis hin zu einem fatalen Verlauf reicht, ist eine genaue Typisierung des Tumors für das weitere Vorrgehen unabdingbar. Insbesondere die Dermatohistologie, in Kombination mit der Immunhistologie und der Molekularbiologie, spielen eine entscheidende Rolle um die richtige Therapiewahl zu treffen.

Abstract

Cutaneous T-cell lymphomas represent extranodal non-Hodgkin lymphomas consisting of mature lymphocytic populations targeting the skin, persisting and proliferating initially in the skin environment. Cutaneous lymphomas reveal a broad variety of clinical manifestations and histological pictures. In contrast to lymphomas of nodal origin, 80 % of all cutaneous lymphomas (CTCL) derive from T-cell populations, the other 10 – 20 % being of B-cell origin (CBCL). The remaining number of lymphomas correspond to rare entities, such as CD4+/CD56+ hematodermic lymphomas, deriving from type-2 dendritic cells. Based on the heterogeneity of these tumours and their varying biological potency, showing long-term benign or fatal clinical courses, there is a strong need for clarifying the type of the tumour, including its cell of origin. Classical histological examination together with immunochemistry and molecular biological techniques are the most important factors for introducing proper treatment.

1 Diese Arbeit ist dem 10-jährigen Jubiläum der Berliner Stiftung für Dermatologie (BSD) und der bisher geleisteten Unterstützung an vielen jüngeren Kollegen in ihrer Weiterbildung und Forschung gewidmet.

Literatur

• 1 Assaf C, Hummel M, Steinhoff M. et al . TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications.  Blood. 2005;  105 503-510
• 2 Assaf C. The clinical impact of T cell receptor rearrangement analysis in cutaneous T cell lymphoma.  Front Radiat Ther Oncol. 2006;  39 16-24
• 3 Assaf C, Hirsch B, Wagner F. et al . Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations.  J Invest Dermatol. 2007;  127 1898-1904
• 4 Assaf C, Gellrich S, Whittaker S. et al . CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.  J Clin Pathol. 2007;  60 981-989
• 5 Balfour E M, Glusac E J, Heald P. et al . Sezary syndrome: cutaneous immunoperoxidase double-labeling technique demonstrates CD4/CD8 ratio non-specificity.  J Cutan Pathol. 2003;  30 437-442
• 6 Bekkenk M W, Jansen P M, Meijer C J. et al . CD56+ haematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature.  Ann Oncol. 2004;  15 1097-1108
• 7 Cerroni L, Volkenandt M, Rieger E. et al . Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas.  J Invest Dermatol. 1994;  102 231-235
• 8 Chan J K, Sin V C, Wong K F. et al . Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.  Blood. 1997;  89 4501-4513
• 9 Child F J. et al . Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma.  Br J Dermatol. 2001;  144 735-744
• 10 Glusac E J. Criterion by criterion, mycosis fungoides.  Am J Dermatopathol. 2003;  25 264-269
• 11 Hoefnagel J J. et al . Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance.  Br J Dermatol. 2003;  149 1183-1191
• 12 Kadin M. et al . Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens.  Am J Pathol. 1985;  119 315-325
• 13 Kamarashev J. et al . Comparative analysis of histological and immunohistological features in mycosis fungoides and Sezary syndrome.  J Cutan Pathol. 1998;  25 407-412
• 14 Kempf W, Ostheeren-Michaelis S, Paulli M. et al . Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC).  Arch Dermatol. 2008;  144 1609-1617
• 15 Klemke C D, Dippel E, Dembinski A. et al . Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides.  J Pathol. 2002;  197 348-354
• 16 Kodama K, Massone C, Chott A. et al . Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients.  Blood. 2005;  106 2491-2497
• 17 Massone C, Kodama K, Kerl H. et al . Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients.  Am J Surg Pathol. 2005;  29 550-560
• 18 Willemze R, Janssen P M, Cerroni L. et al . Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.  Blood. 2008;  111 838-845
• 19 Mirza I, Macpherson N, Paproski S. et al . Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features.  J Clin Oncol. 2002;  20 647-655
• 20 Nakamura S, Suchi T, Koshikawa T. et al . Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract.  Am J Surg Pathol. 1995;  19 284-296
• 21 Petrella T, Comeau M R, Maynadié M. et al . “Agranular CD4+ CD56+ hematodermic neoplasm” (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes.  Am J Surg Pathol. 2002;  26 852-862
• 22 Poszepczynska-Guigne E, Schiavon V, D'Incan M. et al . CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.  J Invest Dermatol. 2004;  122 820-823
• 23 Sandberg Y, Heule F, Lam K. et al . Molecular immunoglobulin/T- cell receptor clonality analysis in cutaneous lymphoproliferations. Experience with the BIOMED-2 standardized polymerase chain reaction protocol.  Haematologica. 2003;  88 659-670
• 24 Schreuder M I. et al . FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma.  J Pathol. 2005;  205 302-310
• 25 Stadler R, Assaf C, Klemke C D. et al . Short German guidelines: Cutaneous lymphomas.  J Dtsch Dermatol Ges. 2008;  6 Suppl 1 S25-S31
• 26 Stein H, Mason D Y, Gerdes J. et al . The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.  Blood. 1985;  66 848-858
• 27 Streubel B, Lamprecht A, Dierlamm J. et al . T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma.  Blood. 2003;  101 2335-2339
• 28 Streubel B, Vinatzer U, Lamprecht A. et al . T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.  Leukemia. 2005;  19 652-658
• 29 Willemze R, Meyer C J, Van Vloten W A. et al . The clinical and histological spectrum of lymphomatoid papulosis.  Br J Dermatol. 1982;  107 131-144
• 30 Willemze R, Jaffe E S, Burg G. et al . WHO-EORTC classification for cutaneous lymphomas.  Blood. 2005;  105 3768-3785

1 Diese Arbeit ist dem 10-jährigen Jubiläum der Berliner Stiftung für Dermatologie (BSD) und der bisher geleisteten Unterstützung an vielen jüngeren Kollegen in ihrer Weiterbildung und Forschung gewidmet.